Case Study: Cenduit achieves 17 rapid COVID‑19 study launches and 12‑day go‑live with IQVIA

Intelligent IRT Design Process for COVID-19 Trials Accelerates Digital Enablement at Sites

Cenduit engaged IQVIA to accelerate digital enablement of sites and speed time-to-first-patient-in for COVID-19 therapeutic and vaccine trials. The customer’s challenge was to find an IRT solution that could go live within two weeks while supporting flexible recruitment capping and drug-supply strategies, eliminating manual unblinding, and meeting sponsor-specific processes and quality standards.

IQVIA delivered a configurable Cenduit IRT universal COVID-19 study design and rapid delivery process, achieving go-live in 12 days (vs. a typical 50‑day timeline), launching 17 COVID-19 studies, and preserving full system flexibility. Measurable impacts included an 80% improvement in turnaround/time saved, a 50% reduction in set-up costs, specification drafting cut from 3 weeks to 3 days, UAT trimmed from 1 week to 1 day, and build times reduced from 4–6 weeks to 2–3 weeks, enabling faster global site activation and improved supply management.

Cenduit